Location Directory

Clinical trials in Tampa, Florida

This page shows live ClinicalTrials.gov search results for Tampa, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

9149

Shown on this page

Current sort

Institutions in Tampa

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Moffitt Cancer Center

Live official records

Open in full search

Conditions: Moderate-to-Severe Atopic Dermatitis
Interventions: Nemolizumab; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years and older
Enrollment: 1,935 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 136
States / cities: Birmingham, Alabama • Guntersville, Alabama • Scottsdale, Arizona + 104 more

Conditions: Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders, Digestive Disorders, Intracranial Aneurysm, Mechanical Circulatory Support, Respiratory Therapy, Aortic, Peripheral Vascular and Venous Disorders, Minimally Invasive Surgical Procedures, Diagnostic Techniques and Procedures, Surgical Procedures, Operative, Renal Insufficiency, Neurovascular, Coronary Artery Disease, Ear, Nose and Throat Disorder
Interventions: Not listed
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 100,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2040
U.S. locations: 136
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 133 more

Conditions: Osteogenesis Imperfecta
Interventions: Bisphosphonate, Setrusumab; Drug · Biological
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 2 Years to 6 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 10 more

Conditions: Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions: Total-Body Irradiation, Thiotepa, Fludarabine, Tacrolimus, Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Methotrexate, Cyclophosphamide, Peripheral Blood Stem Cell, Cyclosporine, Sirolimus, Busulfan, Bone Marrow Aspiration and Biopsy, Echocardiography, Multigated Acquisition Scan, Biospecimen Collection; Radiation · Drug · Biological + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 1 Year to 60 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 3
States / cities: Tampa, Florida • Pittsburgh, Pennsylvania • Seattle, Washington

Conditions: Acne Vulgaris
Interventions: IDP-120 Gel, IDP-120 Vehicle Gel; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 9 Years and older
Enrollment: 585 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 18
States / cities: Rogers, Arkansas • Manhattan Beach, California • San Diego, California + 13 more

Conditions: Multiple Myeloma
Interventions: ABBV-438; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 7
States / cities: Duarte, California • Irvine, California • Denver, Colorado + 4 more

Conditions: Alopecia Areata
Interventions: Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg, Placebo - 50 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 60
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Brea, California + 39 more

Conditions: Fecal Incontinence
Interventions: Iltamiocel, Placebo; Biological · Other
Lead sponsor: Cook MyoSite; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 25
States / cities: La Jolla, California • Orange, California • San Francisco, California + 21 more

Conditions: Systemic Lupus Erythematosus, Rheumatoid Arthritis
Interventions: ABBV-519; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 12
States / cities: Anniston, Alabama • Tustin, California • Clearwater, Florida + 9 more

Conditions: Peanut Allergies
Interventions: MY006 Low Dose, MY006 Mid Dose, MY006 High Dose, MY006 Selected Dose, Placebo (Vehicle); Drug
Lead sponsor: Mabylon AG; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Little Rock, Arkansas • Aurora, Colorado • Colorado Springs, Colorado + 6 more

Conditions: Refractory Metastatic Colorectal Cancer
Interventions: Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil plus Bevacizumab Alone; Drug
Lead sponsor: Delcath Systems Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Duarte, California • Santa Monica, California • Miami, Florida + 6 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Xaluritamig, Abiraterone acetate, Docetaxel, Cabazitaxel; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 46
States / cities: Goodyear, Arizona • Tucson, Arizona • Duarte, California + 37 more

Clinical trials in Tampa, Florida

Filter and sort this location

Institutions in Tampa

Live official records

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Product Surveillance Registry

Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Participants With Acne Vulgaris

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer